Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03794128 · ClinicalTrials.gov registry record
A Study of Personalized Neoantigen Cancer Vaccines
A clinical trial, sponsored by Gritstone bio.
- Completed
- Registry status
- 93
- Enrollment target
NCT03794128: Completed study, sponsored by Gritstone bio.
NCT03794128 is a clinical trial that has completed, run by Gritstone bio. The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03794128 has completed, sponsored by Gritstone bio.
- COMPLETED
- Registry status
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted neoantigens; and, 2) to identify and select patients who may be eligible for a shared neoantigen cancer vaccine where their tumor contains a specific shared mutation and who have the correct HLA allele capable of presenting the neoantigen derived from the tumor-specific mutation.
Interventions
- PROCEDURE Blood collection for research (next-generation sequencing [NGS])
- PROCEDURE Blood collection for research (HLA typing)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2020-05-26 |
What the finished NCT03794128 record still lists
NCT03794128 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 93 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Blood collection for research (next-generation sequencing [NGS]) is the first listed.
NCT03794128 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03794128 about?
NCT03794128 is a clinical study titled "A Study of Personalized Neoantigen Cancer Vaccines". The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted neoantigens; and, 2) to identify and select patients who may be eligible ...
What is the current status of trial NCT03794128?
This trial is currently completed. The enrollment target is 93 participants. The study started on 2018-07-25. Estimated completion is 2020-05-26.
What interventions are being tested in trial NCT03794128?
The interventions under investigation include: Blood collection for research (next-generation sequencing [NGS]) (PROCEDURE), Blood collection for research (HLA typing) (PROCEDURE).
Who is sponsoring clinical trial NCT03794128?
This trial is sponsored by Gritstone bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI